Home » Topics » Regulatory » EMA

EMA
RSS

EMA committee recommends suspending use of Protelos/Osseor

Jan. 15, 2014

EMA accepts Biovest's MAA for BiovaxID

Jan. 14, 2014

Fenfluramine obtains orphan drug designation in the U.S. and E.U. for Dravet syndrome

Jan. 10, 2014

EMA grants accelerated review to Bristol-Myers' MAA for daclatasvir in chronic HCV

Jan. 10, 2014

Cytovir ADV ready to receive orphan drug designation in Europe

Jan. 8, 2014

CHMP gives positive opinion on subcutaneous tocilizumab

Dec. 27, 2013

EMA accepts tolvaptan MAA for ADPKD

Dec. 27, 2013

EMA accepts dalbavancin MAA for review

Dec. 24, 2013

EMA accepts filing of MAA for cangrelor

Dec. 24, 2013

Cometriq receives positive CHMP opinion for thyroid carcinoma

Dec. 23, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...